Global Pharmaceutical Market

Global Pharmaceutical Market
• The global pharmaceutical industry reached

unprecedented heights in 2018, being
estimated at an astounding $1.11 trillion.
• By 2020, this figure is set to rise to $1.43
trillion.
Top Ten Pharma Giants
• Pfizer
• Roche
• Johnson & Johnson
• Sanofi
• Merck
• Novartis
• AbbVie
• Amgen
• GSK
• BMS
Japan Pharma Market
• Japan will be the second fastest growing mature market for solid dose drugs
in 2019 (10 percent growth up from 4.75 percent in 2018) and
• the second fastest global market for growth in biologics (7.5 percent growth),
behind only the USA (7.9 percent growth).
• This forecast places Japan ahead of all EU nations as well as South Korea.
• “Japan’s pharmaceutical industry has long centred on strong innovation and
patented drugs, but they are now observing a dramatic increase in generics
and biosimilars in the market.”
• Growth in the generics market will be supported by the Japanese
government aiming for generics to represent 80% of the pharma market by
September 2020.
• Another important factor is impressive growth prospects for the biologics
sector, which is second only to the US globally. This includes significant
potential for biosimilars.
• However, one of the major challenges the
Japanese pharma market is expected to
encounter during its growth period is ensuring
a stable supply of active pharmaceutical
ingredients to support development.
Highlights of Japan Pharma Industry
• Japan Pharma’s prescription pharmaceutical product revenue is forecast to grow to $69.5bn by
2027* at a CAGR of 1.0%.
• Largest company growth – Ono will experience the highest growth rate out to 2027*.
• Largest company decline – Daiichi Sankyo will experience the largest percentage decline out to
2027*.
• Regional analysis – Strong revenue growth in the US will offset the -0.2% CAGR decline in Japan.
• Most valuable therapy areas – Oncology and CNS will remain the two most valuable therapy
areas for the peer set.
• Most valuable product – Astellas’s Xtandi (enzalutamide) will be the highest selling product
within the peer set out to 2027* at $4.5bn.
• Most valuable pipeline product – Eisai’s aducanumab will become the highest selling pipeline
product with $1.9bn in sales by 2027*.
• Most valuable pipeline – Astellas will have the most valuable pipeline with eight product
launches adding $2.6bn to its topline revenue by 2027*.
• Strategy analysis – Japan Pharma is focusing on key therapy areas of high global unmet need and
turning to collaborations to fuel growth.
1 Takeda 15,594 16,8241.0% Takeda is set to remain the largest grossing pharmaceutical company in
PharmaVitae’s Japan Pharma peer set. Before factoring in its planned acquisition
of Shire, Takeda’s prescription pharmaceutical product revenue will account for
approximately 25% of the peer set’s total pharmaceutical sales throughout the
forecast period. Growth will be driven by continued uptake of Ninlaro in multiple
myeloma, and Entyvio in inflammatory bowel disease.
2 Astellas 11,987 11,551-0.6% PharmaVitae expects Astellas’s prescription pharmaceutical product revenue to
sharply decline in the near term, with three out of four of the company’s largest
products facing generic competition, which is set to cut approximately $2.3bn
from Astellas’s top line over the forecast period. PharmaVitae predicts the
company will return to growth in 2020*, driven by expansion of the peer set’s
largest grossing product Xtandi in prostate cancer. However, PharmaVitae expects
this growth to fail to offset earlier losses, and Astellas’s pharmaceutical product
sales to decline at a CAGR of 0.6% out to 2027*.
3 Otsuka 7,143 9,262 3.1% PharmaVitae predicts Otsuka will experience the largest monetary growth in
prescription pharmaceutical product revenue over the forecast period within the
peer set, driven by psychiatry drugs Rexulti and Abilify Maintena. PharmaVitae
expects Otsuka to be buoyed by assets acquired in the US, and AVP-786 to
become the company’s largest grossing product over the forecast period.
4 Daiichi 7,749 7,255 - PharmaVitae expects Daiichi Sankyo to experience the largest
Sankyo 1.4% percentage decline in prescription pharmaceutical product revenue
over the forecast period within the peer set, as the company faces
generic erosion of its key cardiovascular portfolio.
5 Eisai 4,418 5,162 4.2% PharmaVitae forecasts Eisai to grow at a CAGR of 4.2% over the
forecast period, driven by the success of its oncology and epilepsy
products in offsetting the long-standing generic erosion of Aricept
and Aciphex/Pariet, as well as more recent generic competition for its
largest grossing oncology product Aloxi. Eisai’s long-term outlook
hinges on the success of aducanumab in Alzheimer’s disease, which
PharmaVitae forecasts to become the largest current pipeline asset
in the peer set.
6 Sumitomo 4,303 5,368 0.2% Sumitomo Dainippon is set to experience strong mid-term growth
Dainippon with the extended market exclusivity of its largest grossing product
Latuda, and continued uptake of the company’s respiratory and
oncology portfolios. However, the company will experience a sharp
erosion of its prescription pharmaceutical product revenue in 2024*
as generic competition launches against Latuda, eating away at
previous revenue gains.
7 Shionogi 2,930 3,652 2.7% Shionogi is set to experience modest growth as its portfolio of
CNS and HIV products offsets generic erosion of its leading
dyslipidemia drug Crestor.
8 Ono 2,414 3,361 4.7% Ono is set to make significant progress over the forecast period,
fueled by Opdivo’s success in oncology. PharmaVitae expects Ono
to climb from its number 10 position in the peer set in 2017* to
number 8 by 2027*.
9 Mitsubishi 3,877 3,788 -0.6% Mitsubishi Tanabe’s outlook is negatively impacted by a key
Tanabe patent expiry for Gilenya in 2019, and subsequent end to
associated royalties from Novartis. Growth in the company’s
metabolic disorders portfolio, and successful expansion into the
US with Radicut, will fail to offset earlier losses, and PharmaVitae
expects Mitsubishi Tanabe to decline at a -0.6% CAGR over the
forecast period.
10Kyowa 2,543 2,223 -1.2% PharmaVitae expects Kyowa Hakko Kirin to lose ground over the
Hakko Kirin forecast period due to generic erosion of its hematology portfolio,
and a difficult domestic market. Kyowa Hakko Kirin’s launch
portfolio will add over $750m out to 2027*, but will fail to offset
losses elsewhere.
Grand total 62,958 68,446 1.0%

Exports from India to Japan
Jan-Jun’19
TOP 40 PRODUCTS
Sr. No Products Quantity (kgs)

1 Menthol 177,540
2 Paracetamol 120,000
3 Ibuprofen 50,250
4 Erythromycin 34,424
5 Sulfamethoxazole 32,000
6 Lecithin 28,087
7 NIACINAMIDE 26,425
8 LANTHANUM CARBONATE 20,044
9 FENOFIBRATE 13,798
10 KETOPROFEN 13,500
11 7 AVNA 12,300
12 Fexofenadine 11,378
13 DILTIAZEM 10,000
14 PSEUDOEPHEDRINE 9,000
15 Clopidogrel 8,608
16 VALACYCLOVIR 8,378
17 AMLODIPINE BESILATE 8,369
18 GLUCOSAMINE 8,109
19 Paraben 8,000
20 Tramadol 7,813
21 Famotidine 7,084
22 DEXTROMETHORPHAN 5,705
23 Lidocaine 5,550
24 GCLE 5,010
25 Valsartan 4,603
26 Diclofenac 3,700
27 Sertraline 3,540
28 Nicotinamide 3,300
29 FUROSEMIDE 3,083
30 Flurbiprofen 2,504
31 Metformin 2,400
32 Domperidone 1,656
33 ATORVASTATIN 1,405
34 Roxithromycin 1,377
35 Pregabalin 1,365
36 LEVETIRACETAM 1,347
37 CAFFEINE 1,250
38 Meropenem 1,227
39 GLICLAZIDE 1,169
40 Glycerine 1,000

Global Pharmaceutical Market

Uploaded by

Copyright:

Available Formats

Global Pharmaceutical Market

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Global Pharmaceutical Market

Uploaded by

Copyright:

Available Formats

Global Pharmaceutical Market

• The global pharmaceutical industry reached

Grand total 62,958 68,446 1.0%

Sr. No Products Quantity (kgs)

You might also like